Recently Featured

Medical journal retracts Tavneos pivotal study article, complicating Amgen’s defense effort

July 21, 2026
Amgen’s rare disease treatment, Tavneos, faces a significant setback following the retraction of its pivotal study article by a prominent medical journal. This development comes amid increasing scrutiny from the FDA regarding the drug’s safety and efficacy, raising concerns about its market viability. The retraction not only undermines the credibility of the clinical data supporting…

AstraZeneca to Pay $34 Million to Settle Kickback Allegations in Texas

July 20, 2026
AstraZeneca has agreed to pay $34 million to settle a lawsuit alleging that the company engaged in illegal kickback practices to incentivize healthcare providers to prescribe its products covered by Texas Medicaid. This settlement underscores the ongoing scrutiny pharmaceutical companies face regarding compliance with federal and state regulations surrounding marketing practices and reimbursement protocols. The…

Beeline Secures Over $426 Million in Series A Funding for Immune Drug Development

July 20, 2026
Beeline has successfully extended its Series A funding round, amassing over $426 million to further its development of immune therapies derived from Bristol Myers Squibb’s portfolio. This significant financial boost underscores the growing investor confidence in Beeline’s innovative approach to immune drug development. Founded by Bain Capital, Beeline’s strategic focus on leveraging existing Bristol Myers…

Ongoing Cases